Soad El Ghazouani
Director/Board Member at AFFLUENT MEDICAL
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michel Therin | M | - | 2 years | |
Philippe Pouletty | M | 65 | 6 years | |
Sarah Sorrel | F | - |
T-Heart SAS
T-Heart SAS Miscellaneous Commercial ServicesCommercial Services T-Heart SAS is an investment holding company with interest in research and development services on natural sciences sector. The company was founded on December 06, 2018 and is headquartered in Paris, France. | 2 years |
Bernard Gilly | M | 67 |
T-Heart SAS
T-Heart SAS Miscellaneous Commercial ServicesCommercial Services T-Heart SAS is an investment holding company with interest in research and development services on natural sciences sector. The company was founded on December 06, 2018 and is headquartered in Paris, France. | - |
Christophe Giot | M | - | 2 years | |
Luc Parisot | M | - | - | |
Claire André | F | - | 1 years | |
Olivier Belamy | M | - | 1 years | |
Céline Buard | F | - | - | |
Sébastien Ladet | M | - | 2 years | |
Olivier Pieron | M | - | - | |
Eric Jague | M | - | - | |
Francois Laborde | M | - | - | |
Ellen Roche | M | - | - | |
Dominique Carouge | M | - | - | |
Claire Corot | F | - | - | |
Patrick Coulombier | M | - | 6 years | |
Alexia Perouse | F | - |
T-Heart SAS
T-Heart SAS Miscellaneous Commercial ServicesCommercial Services T-Heart SAS is an investment holding company with interest in research and development services on natural sciences sector. The company was founded on December 06, 2018 and is headquartered in Paris, France. | 6 years |
Benjamin Renault | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Chantal Parpex | M | 76 |
Bioring SA
Bioring SA Medical SpecialtiesHealth Technology Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development | - |
Michel Finance | M | - | - | |
Jean-Michel Malbrancq | M | - | 4 years | |
Jerome Geoffroy | M | - | - | |
Jean-Claude Manini | M | - |
Bioring SA
Bioring SA Medical SpecialtiesHealth Technology Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development | - |
Gilles Brisson | M | 72 |
Bioring SA
Bioring SA Medical SpecialtiesHealth Technology Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development | - |
Afksendyios Kalangos | M | - |
Bioring SA
Bioring SA Medical SpecialtiesHealth Technology Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development | 13 years |
Alain Chevallier | M | 70 |
Bioring SA
Bioring SA Medical SpecialtiesHealth Technology Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development | - |
Ingrid Sophie Marianne Rayez | F | - |
Bioring SA
Bioring SA Medical SpecialtiesHealth Technology Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development | - |
Philippe Le Goff | M | - |
Bioring SA
Bioring SA Medical SpecialtiesHealth Technology Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development | 13 years |
Daniel Hayoz | M | - | 4 years | |
Jean-François Le Bigot | M | - | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
France | 24 | 77.42% |
Switzerland | 7 | 22.58% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Soad El Ghazouani
- Personal Network